- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06129851
Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer
Quantifying Optimal Relugolix Duration With Radiation in High Risk Prostate Cancer (QURE-PC)
Study Overview
Status
Conditions
Intervention / Treatment
- Other: Questionnaire Administration
- Procedure: Magnetic Resonance Imaging
- Procedure: Computed Tomography
- Procedure: Biospecimen Collection
- Radiation: Brachytherapy
- Radiation: External Beam Radiation Therapy
- Drug: Relugolix
- Procedure: Dual X-ray Absorptiometry
- Procedure: Bone Scan
- Procedure: PSMA PET Scan
Detailed Description
PRIMARY OBJECTIVE:
I. To compare the biochemical recurrence rate between 12 and 24 months of relugolix in patients with high risk prostate cancer treated with combination external beam radiation and brachytherapy.
SECONDARY OBJECTIVES:
I. To compare the composite quality of life in patient treated with 12 months and 24 months of relugolix as assessed by the Expanded Prostate Composite Index Short Form (EPIC-26) instrument.
II. To compare the treatment related toxicity between 12 months and 24 months of relugolix as assessed by Common Terminology Criteria for Adverse Events version 5.0. (CTCAE v 5.0) criteria.
III. To compare the rate of major adverse cardiovascular events (MACE) in patients treated with 12 and 24 months of relugolix.
IV. To establish the rate of patient compliance using patient reported drug diary.
V. To compare the rate of testosterone recovery after 12 and 24 months of relugolix.
EXPLORATORY OBJECTIVE:
I. To establish Decipher genomic classifier as predictor of cancer control.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive relugolix orally (PO) once daily (QD). Cycles repeat every 3 months for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 30 to 180 days after start of relugolix, patients undergo brachytherapy and external beam radiation over 25 fractions. Patients undergo bone scan, computed tomography (CT) or magnetic resonance imaging (MRI) or prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scan during screening. Patients also undergo dual x-ray absorptiometry (DEXA) scan and may optionally undergo blood sample collection throughout the trial.
ARM B: Patients receive relugolix PO QD. Cycles repeat every 3 months for 24 months in the absence of disease progression or unacceptable toxicity. Beginning 30 to 180 days after start of relugolix, patients undergo brachytherapy and external beam radiation over 25 fractions. Patients undergo bone scan, CT or MRI or PSMA PET scan during screening. Patients also undergo DEXA scan and may optionally undergo blood sample collection throughout the trial.
After completion of study treatment, patients in Arm A are followed up every 3 months for 12 months and then every 6 months for up to 36 months and patients in Arm B are followed up every 6 months for up 36 months.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Cancer Center
-
Principal Investigator:
- Xinglei Shen
-
Contact:
- Xinglei Shen
- Phone Number: 913-588-3600
- Email: xshen@kumc.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Ability of participant or Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent
- Age ≥ 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1
- Life expectancy > 5 years
Patient diagnosed with National Comprehensive Cancer Network (NCCN) high risk and very high risk prostate cancer.
High risk is defined as:
- T3a or
- Grade group 4 or 5 or
- Prostate-specific antigen (PSA) > 20 ng/mL
Very high risk is defined as:
- T3b to T4 or
- Primary Gleason pattern 5 or
- Two or three high-risk features or
- > 4 cores with grade group 4 or 5
- Eligible for treatment with combination brachytherapy, external beam radiation, and ADT
- Leukocytes >= 1.0 K/UL
- Platelets >= 100 K/UL
- Hemoglobin ≥ 9 g/dL
- Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x upper limit of normal (ULN)
- Men with partners of child-bearing potential must agree to practice sexual abstinence or to use the forms of contraception listed for the duration of study participation and for 2 weeks following completion of relugolix therapy
Exclusion Criteria:
- Simultaneously enrolled in any therapeutic clinical trial
- Current or anticipating use of other anti-neoplastic or investigational agents while participating in this study
- Diagnosed with a psychiatric illness or is in a social situation that would limit compliance with study requirements
- Has a known allergic reaction to any excipient or component contained in the study drug formulation
- Active grade 3 (per the National Cancer Institute [NCI] CTCAE, version 5.0) or higher viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study treatment
- Current androgen deprivation therapy (unless testosterone > 50 ng/dL). Please note prior or concurrent bicalutamide at 50 mg/daily or less is allowed. Prior androgen deprivation therapy is allowed if testosterone has recovered to > 50 ng/dL
- Prolonged echocardiogram corrected QT (QTc) interval > 440 ns
- Prior pelvic therapy that would significantly overlap with radiation treatment fields
- Prior prostatectomy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A (relugolix, brachytherapy, external beam radiation)
Patients receive relugolix PO QD.
Cycles repeat every 3 months for 12 months in the absence of disease progression or unacceptable toxicity.
Beginning 30 to 180 days after start of relugolix, patients undergo brachytherapy and external beam radiation over 25 fractions.
Patients undergo bone scan, CT or MRI or PSMA PET scan during screening.
Patients also undergo DEXA scan and may optionally undergo blood sample collection throughout the trial.
|
Ancillary studies
Undergo MRI
Other Names:
Undergo CT
Other Names:
Undergo blood sample collection
Other Names:
Undergo brachytherapy
Other Names:
Undergo external beam radiation therapy
Other Names:
Given PO
Other Names:
Undergo DEXA scan
Other Names:
Undergo bone scan
Other Names:
Undergo PSMA PET
Other Names:
|
Experimental: Arm B (relugolix, brachytherapy, external beam radiation)
Patients receive relugolix PO QD.
Cycles repeat every 3 months for 24 months in the absence of disease progression or unacceptable toxicity.
Beginning 30 to 180 days after start of relugolix, patients undergo brachytherapy and external beam radiation over 25 fractions.
Patients undergo bone scan, CT or MRI or PSMA PET scan during screening.
Patients also undergo DEXA scan and may optionally undergo blood sample collection throughout the trial.
|
Ancillary studies
Undergo MRI
Other Names:
Undergo CT
Other Names:
Undergo blood sample collection
Other Names:
Undergo brachytherapy
Other Names:
Undergo external beam radiation therapy
Other Names:
Given PO
Other Names:
Undergo DEXA scan
Other Names:
Undergo bone scan
Other Names:
Undergo PSMA PET
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biochemical recurrence
Time Frame: Up to 3 years
|
Will be defined as serum prostate-specific antigen (PSA) level of nadir + 2 ng/mL by blood test.
|
Up to 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite quality of Life
Time Frame: Up to 5 years
|
Will be assessed by the Expanded Prostate Composite Index Short Form (EPIC-26) and will be compared between the 2 arms in terms of hormonal domain and sexual domain of EPIC-26.
An area under the curve (AUC) metric will be utilized to account for the overall quality of life from baseline through 36 months for each patient.
A mixed effect model will be employed to construct an estimate of the difference in AUC between Arms A and B, including fixed effects of time, arm, and baseline characteristics (two or three covariates depending on the available sample size).
A two-sample t-test with a significance level of 0.05 will be performed.
|
Up to 5 years
|
Incidence of adverse events
Time Frame: Up to 5 years
|
Will be assessed by Common Terminology Criteria for Adverse Events version 5.0 and will be reported descriptively.
|
Up to 5 years
|
Incidence of major adverse cardiovascular events
Time Frame: Up to 5 years
|
Will be assessed by medical record review and will be reported descriptively.
|
Up to 5 years
|
Participant compliance
Time Frame: Up to 2 years
|
Will be assessed by patient study diary.
|
Up to 2 years
|
Time to testosterone recovery
Time Frame: Up to 5 years
|
Will be assessed by blood tests and the percentage of patients in each arm who achieved baseline level or minimum 280 ng/dL will be reported at 3-month intervals up through 36 months after treatment completion.
|
Up to 5 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Xinglei Shen, University of Kansas
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Androgen Antagonists
- Relugolix
Other Study ID Numbers
- STUDY00150674 (Other Identifier: University of Kansas Cancer Center)
- P30CA168524 (U.S. NIH Grant/Contract)
- NCI-2023-09079 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage IV Prostate Cancer AJCC v8
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
National Cancer Institute (NCI)Active, not recruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditionsUnited States, Puerto Rico
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Refractory Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage IV Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB... and other conditionsUnited States
-
Jonsson Comprehensive Cancer CenterRecruitingProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)RecruitingStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingProstate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer... and other conditionsUnited States
Clinical Trials on Questionnaire Administration
-
Fondazione Don Carlo Gnocchi OnlusUnknown
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
Istanbul Aydın UniversityCompleted
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingLi-Fraumeni SyndromeUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Malignant Neoplasm | Caregiver | Advanced Malignant Neoplasm | Locally Advanced Malignant NeoplasmUnited States
-
Istituto Auxologico ItalianoCompletedObesity | Eating DisordersItaly
-
Vanderbilt-Ingram Cancer CenterTerminatedMalignant NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedMalignant NeoplasmUnited States
-
Federico II UniversityUnknownSleep Disorder | Renal Transplant | Hypertension; NephropathyItaly